[Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Iyoda
Kenya
K
Department of Gastroenterology, Osaka National Hospital.
Kato
Michio
M
D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007372:Interferons / Q000008:administration & dosage*; D007564:Japan; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage; D016896:Treatment Outcome
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons